The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.

ABSTRACT: PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer^1,2, who were germline BRCA1 and BRCA2 wild type³. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)⁴, and secondary end points included event-free survival (EFS) and overall survival (OS)⁵. pCR was achieved in 51% of patients in the research arm and 52% in the control arm

SUBMITTER: Abraham JE 

PROVIDER: S-EPMC11136660 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature